Clinical Trial

Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2025 (before its estimated May 4, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, open-label, multicenter, prospective clinical trial aimed at evaluating the efficacy and safety of orelabrutinib combined with rituximab for the previously untreat MZL
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-20.
Status change: Not Yet Recruiting → Recruiting 2025-06-14
Trial Details
NCT Number NCT06700798
Lead Sponsor Fei Li
Conditions Marginal Zone Lymphoma(MZL)
Enrollment 90 participants
Start Date 2024-12-01
Primary Completion 2026-05-04 (estimated)
Study Completion 2027-12-04 (estimated)
Updated on ClinicalTrials.gov 2025-06-17